230 related articles for article (PubMed ID: 22975570)
21. Focal bone lesions in HIV-positive patient treated with tenofovir.
Mangioni D; Bandera A; Muscatello A; Squillace N; Crivellaro C; Guerra L; Messa C; Gori A
BMC Infect Dis; 2014 Mar; 14():131. PubMed ID: 24602357
[TBL] [Abstract][Full Text] [Related]
22. Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Quinn KJ; Emerson CR; Dinsmore WW; Donnelly CM
Int J STD AIDS; 2010 Feb; 21(2):150-1. PubMed ID: 20090006
[No Abstract] [Full Text] [Related]
23. Decreased expression of megalin and cubilin and altered mitochondrial activity in tenofovir nephrotoxicity.
Cez A; Brocheriou I; Lescure FX; Adam C; Girard PM; Pialoux G; Moestrup SK; Fellahi S; Bastard JP; Ronco P; Plaisier E
Hum Pathol; 2018 Mar; 73():89-101. PubMed ID: 29309806
[TBL] [Abstract][Full Text] [Related]
24. Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Wainwright E; Sherrard J; Duncan S; Shine B; Dorrell L
Int J STD AIDS; 2013 Jul; 24(7):579-81. PubMed ID: 23970775
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Giacomet V; Cattaneo D; Viganò A; Nannini P; Manfredini V; Ramponi G; Clementi E; Zuccotti GV
Pediatr Infect Dis J; 2013 Oct; 32(10):e403-5. PubMed ID: 24067562
[TBL] [Abstract][Full Text] [Related]
26. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
[TBL] [Abstract][Full Text] [Related]
27. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
[TBL] [Abstract][Full Text] [Related]
28. Long-term Renal Outcome of Biopsy-proven Acute Tubular Necrosis and Acute Interstitial Nephritis.
Kim H; Jo SK; Ahn SY; Kwon YJ; Lee H; Oh J; Chin HJ; Lim K; Lee J; Yang J; Kim MG; Cho WY; Oh SW
J Korean Med Sci; 2020 Jul; 35(26):e206. PubMed ID: 32627439
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir-induced osteomalacia.
Wanner DP; Tyndall A; Walker UA
Clin Exp Rheumatol; 2009; 27(6):1001-3. PubMed ID: 20149322
[TBL] [Abstract][Full Text] [Related]
30. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Kinai E; Hanabusa H
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
[TBL] [Abstract][Full Text] [Related]
31. Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.
Pavie J; Scemla A; Bouldouyre MA; Pillebout E; Verine J; Molina JM
AIDS Patient Care STDS; 2011 Aug; 25(8):457-60. PubMed ID: 21751874
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
33. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Young J; Wang Q; Fux CA; Bernasconi E; Furrer H; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
HIV Med; 2014 Sep; 15(8):505-10. PubMed ID: 24641488
[TBL] [Abstract][Full Text] [Related]
34. Eosinophiluria and drug-induced acute interstitial nephritis.
Landais P; Goldfarb B; Kleinknecht D
N Engl J Med; 1987 Jun; 316(26):1664. PubMed ID: 3587304
[No Abstract] [Full Text] [Related]
35. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels.
Kinai E; Hanabusa H
AIDS; 2005 Nov; 19(17):2031-3. PubMed ID: 16260911
[TBL] [Abstract][Full Text] [Related]
36. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.
Sánchez-Conde M; Gil P; Sánchez-Somolinos M; Gonzalez-Lahoz J; Soriano V
HIV Clin Trials; 2005; 6(5):278-80. PubMed ID: 16306034
[TBL] [Abstract][Full Text] [Related]
37. Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Manosuthi W; Prasithsirikul W; Tantanathip P; Chimsuntorn S; Nilkamhang S; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):643-50. PubMed ID: 21706942
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Nishijima T; Komatsu H; Higasa K; Takano M; Tsuchiya K; Hayashida T; Oka S; Gatanaga H
Clin Infect Dis; 2012 Dec; 55(11):1558-67. PubMed ID: 22955427
[TBL] [Abstract][Full Text] [Related]
39. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients.
Rho M; Perazella MA
Curr Drug Saf; 2007 May; 2(2):147-54. PubMed ID: 18690961
[TBL] [Abstract][Full Text] [Related]
40. Effect of tenofovir on renal glomerular and tubular function.
Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
